News

Overview of R2 Regimen for Relapsed Follicular Lymphoma

Andre Goy, M.D., chief, division of Lymphoma, chair and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2 regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.

READ FULL ARTICLE ON TARGETEDONC.COM